126 related articles for article (PubMed ID: 14748202)
21. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
Brugts JJ; Isaacs A; Boersma E; van Duijn CM; Uitterlinden AG; Remme W; Bertrand M; Ninomiya T; Ceconi C; Chalmers J; MacMahon S; Fox K; Ferrari R; Witteman JC; Danser AH; Simoons ML; de Maat MP
Eur Heart J; 2010 Aug; 31(15):1854-64. PubMed ID: 20538738
[TBL] [Abstract][Full Text] [Related]
22. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Ferrari R;
Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
24. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
25. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
26. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
27. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
28. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
van der Leeuw J; Oemrawsingh RM; van der Graaf Y; Brugts JJ; Deckers JW; Bertrand M; Fox K; Ferrari R; Remme WJ; Simoons ML; Boersma E; Visseren FL
Int J Cardiol; 2015 Mar; 182():194-9. PubMed ID: 25577762
[TBL] [Abstract][Full Text] [Related]
29. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
30. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
Brugts JJ; Boersma E; Simoons ML
Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
[TBL] [Abstract][Full Text] [Related]
31. PERSUADE...(a EUROPA sub-study)...results: perindopril protects diabetic patients with coronary disease from cardiovascular death and heart attacks.
Cardiovasc J S Afr; 2004; 15(3):146. PubMed ID: 15356914
[No Abstract] [Full Text] [Related]
32. Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
Danchin N
Arch Cardiovasc Dis; 2009 Feb; 102(2):81-3. PubMed ID: 19303573
[No Abstract] [Full Text] [Related]
33. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
Cleland JG; Tendera M; Adamus J; Freemantle N; Polonski L; Taylor J;
Eur Heart J; 2006 Oct; 27(19):2338-45. PubMed ID: 16963472
[TBL] [Abstract][Full Text] [Related]
34. [Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2007 Oct; 62(10):639-43. PubMed ID: 18069576
[TBL] [Abstract][Full Text] [Related]
35. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
Mackay JA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
[TBL] [Abstract][Full Text] [Related]
36. The EUROPA trial: design, baseline demography and status of the substudies.
Gomma AH; Fox KM
Cardiovasc Drugs Ther; 2001 Mar; 15(2):169-79. PubMed ID: 11669411
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.
Battes L; Barendse R; Steyerberg EW; Simoons ML; Deckers JW; Nieboer D; Bertrand M; Ferrari R; Remme WJ; Fox K; Takkenberg JJ; Boersma E; Kardys I
Am J Cardiol; 2013 Jul; 112(1):27-33. PubMed ID: 23558041
[TBL] [Abstract][Full Text] [Related]
38. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
Redekop WK; Orlewska E; Maciejewski P; Rutten FF; Niessen LW
Pharmacoeconomics; 2008; 26(10):861-77. PubMed ID: 18793033
[TBL] [Abstract][Full Text] [Related]
39. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
40. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study.
Rodriguez-Granillo GA; de Winter S; Bruining N; Ligthart JM; García-García HM; Valgimigli M; de Feyter PJ;
Eur Heart J; 2007 Oct; 28(19):2326-31. PubMed ID: 17766284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
